Preface, Main Points, Chapters 1–6

References 

1. Barrington SF, Kettle AG, O’Doherty MJ, et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur. J. Nucl. Med. 1996;23:123–130
   • MEDLINE
   • CrossRef
2. British Institute of Radiology, 1999. Patients leaving hospital after administration of radioactive substances. Br. J. Radiol. 72, 121–125.
3. Buchan RCT, Brindle MA. Radioiodine therapy to out-patients – the contamination hazard. Br. J. Radiol. 1970;43:479–483
   • MEDLINE
   • CrossRef
4. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 hyperthyroid therapy. J. Nucl. Med. 1991;32:169–173
   • MEDLINE
5. Driver I, Packer S. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma. Nucl. Med. Communic. 2001;22:1129–1132
6. Hanscheid H, Lassmann M, Reiners CHR, Aulbach F. Monitoring of ¹³¹I incorporation in nuclear medicine personnel by self accomplished measurements. Nuklearmedizin. 2003;42:45–49
   • MEDLINE
7. Hilditch TE, Connell JMC, Davies DL, et al. Radiological protection guidance for radioactive patients – new data for therapeutic ¹³¹I. Nucl. Med. Communic. 1991;12:485–495
8. Ibis E, Wilson CR, Collier BD, et al. Iodine-131 contamination from thyroid cancer patients. J. Nucl. Med. 1992;33:2110–2115
   • MEDLINE
9. International Atomic Energy Agency, 1996. Basic Safety Standards. IAEA,Vienna.
10. International Atomic Energy Agency, 2002a. Radiological Protection for Medical Exposure to Ionizing Radiation, Safety Guide No. RS-G-1.5. IAEA, Vienna.
11. International Atomic Energy Agency, 2002b. Detection of Radioactive Materials at Borders, IAEA-TECDOC-1312. IAEA, Vienna.
12. International Commission on Radiological Protection, 1991. 1990 Recommendations of the International Commision of Radiological Protection. ICRP Publication 60, Ann. ICRP 21 (1–3).
13. International Commission on Radiological Protection, 1996. Radiological protection and safety in medicine. ICRP Publication 73, Ann. ICRP 26 (2).
14. Jacobson AP, Plato PA, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am. J. Public Health. 1978;68:225–230
    • MEDLINE
    • CrossRef
15. Lassmann M, Hanscheid H, Schelper LF. Measurement of incorporation in family members of patients with benign thyroid disease after radioiodine therapy. Nuklearmedizin. 1998;37:120–123
    • MEDLINE
16. Lubin E. Definitive improvement in the approach to the treated patient as a radioactive source. J. Nucl. Med. 2002;43:364–365
    • MEDLINE
17. National Council on Radiation Protection and Measurements, 1995. Dose Limits for Individuals who Receive Exposure from Radionuclide Therapy Patients. NCRP Commentary No. 11. NCRP, Bethesda.
18. Nishizawa K, Ohara K, Ohshima M, et al. Monitoring of I excretions and used materials of patients treated with ¹³¹I. Health Phys. 1980;38:467–481
    • MEDLINE
    • CrossRef
19. O’Doherty MJ, Kettle AG, Eustance CNP, et al. Radiation dose rates from adult patients receiving ¹³¹I therapy for hyperthyroidism. Nucl. Med. Communic. 1993;14:160–168
20. Schomaecker K, Fischer T, Gaidouk M, et al. Exhalation of iodine-131 after radioiodine therapy: time dependence and chemical form. J. Nucl. Med. 2000;41(Suppl.):251P
21. Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line-source versus point-source model. J. Nucl. Med. 2002;43:1241–1244
    • MEDLINE
22. Thompson W, Williams NR, Harding LK. A model of excreted activities of radiopharmaceuticals from patients to the drains. Eur. J. Nucl. Med. 1994;21:876
23. United Nations Scientific Committee on the Effects of Atomic Radiation, 2000. Sources and Effects of Ionizing Radiation. 2000 Report to the General Assembly with Annexes, United Nations, Vienna.
24. Wellner U, Eschner W, Hillger W, et al. The exposure of relatives to patients of a nuclear medicine ward after radioiodine therapy by inhalation of ¹³¹I in their home. Nuklearmedizin. 1998;37:113–119
    • MEDLINE